Drug Trial Radar · NCT04091126
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
118
Actual
Start
Dec 18, 2019
Primary completion
Jun 2, 2025
Study completion Mar 10, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Selected doses of belantamab mafodotin will be administered as intravenous infusion.
BortezomibDrug
Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
LenalidomideDrug
Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
DexamethasoneDrug
Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab MafodotinTime frame: Up to 63 days
- Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 284 weeks
Locations
30 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Westwood, Kansas
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Newcastle, New South Wales, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Poitiers, France
GSK Investigational Site
Dresden, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Schwerin, Germany
GSK Investigational Site
Tübingen, Germany
GSK Investigational Site
Bologna, Italy
GSK Investigational Site
Meldola FC, Italy
GSK Investigational Site
Lublin, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Málaga, Spain
GSK Investigational Site
PamplonaNavarra, Spain
GSK Investigational Site
Pozuelo de AlarcOn Madr, Spain
GSK Investigational Site
Santander, Spain
GSK Investigational Site
Badalona, Barcelona, Spain
GSK Investigational Site
Leicester, United Kingdom
GSK Investigational Site
Oxford, United Kingdom
GSK Investigational Site
Southampton, Hampshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.